Efficacy of double-coated probiotics for irritable bowel syndrome: a randomized double-blind controlled trial
Efficacy of double-coated probiotics for irritable bowel syndrome: a randomized double-blind controlled trial
复制标题
DOI：
10.1007/s00535-016-1224-y
复制
发表时间：
2017-04-01
影响因子：
6.3
通讯作者：
Kim, Hojun
中科院分区：
文献类型：
--
作者：
Han, Kyungsun;Wang, Jinghwa;Kim, Hojun
本研究的目的是在一项随机双盲临床试验中阐明双包被益生菌补充剂（Duolac Care）对腹泻型肠易激综合征症状的影响。方法将50例腹泻型肠易激综合征患者随机分为非包衣组和双包衣组，每天2粒，每粒含50亿细菌。从适当的救济问卷的数据被用于评估主要结果。收集大便频率和布里斯托尔大便量表的每日记录，每周使用100毫米视觉模拟量表的症状日记，以及贝克抑郁量表。分析研究前后的血液检查，包括血细胞计数、白细胞介素-10、肿瘤坏死因子α和诱导型一氧化氮合酶，以及调节性T细胞-CD4 + CD25（高）+ T细胞、CD4 + LAP + T细胞和CD25（高）+ LAP + T细胞。采用实时定量聚合酶链反应法研究肠道菌群的变化。结果充分缓解问卷的回答表明，双包衣组的整体不适有显著改善，与未包衣的益生菌相比，双包衣益生菌对正常大便与硬大便或水样大便的比例有更好的影响。这可能是由于肠道菌群的变化，因为我们的相关分析显示双歧杆菌与排便急迫性之间存在显著的负相关。结论双涂层益生菌制剂可作为治疗腹泻型肠易激综合征的候选制剂。
Background The purpose of this study was to elucidate the effects of a dual-coated probiotic supplement (Duolac Care) on symptoms of diarrhea-predominant irritable bowel syndrome in a randomized double-blind clinical trial.Methods Fifty subjects with diarrhea-predominant irritable bowel syndrome were randomly assigned to either the non-coating group or the dual- coating group in order to receive two capsules per day of multi-species probiotics containing 5 billion bacteria per capsule for 4 weeks. Data from an adequate relief questionnaire were used in assessment of primary outcome. Daily records of stool frequencies and the Bristol stool scale, a weekly symptom diary using 100-mm visual analog scale, and Beck depression inventories were collected. Blood tests including blood cell counts, interleukin-10, tumor necrosis factoralpha and inducible nitric oxide synthase, and regulatory T cells-CD4 + CD25 (high) + T cells, CD4 + LAP + T cells and CD25 (high) + LAP + T cells-were analyzed before and after the study. The shift of gut microbiota was investigated using a quantitative real-time polymerase chain reaction assay.Results Responses to the adequate relief questionnaire indicated significant improvement in overall discomfort in the dual-coating group and the ratio of normal stools to hard or watery stools had a better effect from dual-coated probiotics compared to non-coated probiotics. This may be due to a shift of intestinal microbiota, as our correlation analysis showed significant negative correlation between Bifidobacterium and urgency of defecation.Conclusions Our result implies that dual-coating layers of probiotic supplement can be a candidate for treatment of diarrhea-predominant irritable bowel syndrome.